Pre-eclampsia is a major cause of perinatal mortality. Glutamate plays a critical function in the promotion of a healthy pregnancy. Therefore, the aim of this study was to determine the extent of the correlation between pre-eclampsia and 4-hydroxyglutamate acid. This is a case-control study that was conducted on a sample of 100 pregnant women in the third trimester. The study group consisted of 26 cases of mild pre-eclampsia and 24 cases of severe pre-eclampsia, while the control group consisted of 50 normotensive pregnant women. In addition to human 4-hydroxyglutamate, which was measured by ELISA, liver function test, renal function test, uric acid, serum lactate dehydrogenase (LDH), complete blood picture, and urine albumin were performed for all patients. The mean level of 4-hydroxyglutamate was significantly higher in the case group (mean ± SD = 243 ± 59 pg/ml) than in the control group (mean ± SD = 90 ± 45 pg/ml), with a range of 29-351 pg/ml vs 4-185 pg/ml and a p-value of < 0.0001/ml. Severe pre-eclampsia patients had higher mean 4-hydroxyglutamate levels (257.88 ± 43.436 pg/ml) than mild cases (229.77 ± 68.789 pg/ml), although the difference was non-significant. A 4-hydroxyglutamate level of ≥ 142.5 was shown to be a highly sensitive (92%) and specific (85.2%) indicator of pre-eclampsia using the receiver operator characteristics curve. A 4-hydroxyglutamate level of ≥ 142.5 led to a 5.75-fold higher risk of pre-eclampsia. The level of 4-hydroxy glutamate was increased significantly in pregnant women with pre-eclampsia compared to healthy women and could be used as a predicting marker with high sensitivity.
References
1.
Myatt L, Clifton RG, Roberts JM, Spong CY, Hauth JC, Varner MW, et al. First-Trimester Prediction of Preeclampsia in Nulliparous Women at Low Risk. Obstetrics & Gynecology. 2012;119(6):1234–42.
2.
Fazal RS, Chandru S, Biswas M. Evaluation of total LDH and its isoenzymes as markers in preeclampsia. Journal of Medical Biochemistry. 2019;0(0).
3.
Shi J, Yang Z, Li F, Wang G. Preliminary study of human serum albumin level in early warning onset of pre-eclampsia. Zhonghua Fu Chan Ke Za Zh. 2020;55(1):29–35.
4.
Bellos I, Pergialiotis V, Loutradis D, Daskalakis G. The prognostic role of serum uric acid levels in preeclampsia: A meta‐analysis. The Journal of Clinical Hypertension. 2020;22(5):826–34.
5.
Shin EK, Kang HY, Yang H, Jung EM, Jeung EB. The Regulation of Fatty Acid Oxidation in Human Preeclampsia. Reproductive Sciences. 2016;23(10):1422–33.
6.
Aye ILMH, Aiken CE, Charnock-Jones DS, Smith GCS. Placental energy metabolism in health and disease—significance of development and implications for preeclampsia. American Journal of Obstetrics and Gynecology. 2022;226(2):S928–44.
7.
Mayrink J, Leite DF, Nobrega GM, Costa ML, Cecatti JG. Prediction of pregnancy-related hypertensive disorders using metabolomics: a systematic review. BMJ Open. 2022;12(4):e054697.
8.
Briceño-Pérez C, Briceño-Sanabria L, Vigil-De Gracia P. Prediction and Prevention of Preeclampsia. Hypertension in Pregnancy. 2009;28(2):138–55.
9.
Gunnarsdottir J, Stephansson O, Cnattingius S, Åkerud H, Wikström AK. Risk of placental dysfunction disorders after prior miscarriages: a population-based study. American Journal of Obstetrics and Gynecology. 2014;211(1):34.e1-34.e8.
10.
Luo Z, An N, Xu H, Larante A, Audibert F, Fraser WD. The effects and mechanisms of primiparity on the risk of pre‐eclampsia: a systematic review. Paediatric and Perinatal Epidemiology. 2007;21(s1):36–45.
11.
Farzaneh F, Tavakolikia Z, Soleimanzadeh Mousavi SH. Assessment of occurrence of preeclampsia and some clinical and demographic risk factors in Zahedan city in 2017. Clinical and Experimental Hypertension. 2019;41(6):583–8.
12.
Wu X, Xie C, Zhang Y, Fan Z, Yin Y, Blachier F. Glutamate–glutamine cycle and exchange in the placenta–fetus unit during late pregnancy. Amino Acids. 2015;47(1):45–53.
13.
Silva LM, Coolman M, Steegers EA, Jaddoe VW, Moll HA, Hofman A, et al. Low socioeconomic status is a risk factor for preeclampsia: the Generation R Study. Journal of Hypertension. 2008;26(6):1200–8.
14.
Ogawa K, Urayama KY, Tanigaki S, Sago H, Sato S, Saito S, et al. Association between very advanced maternal age and adverse pregnancy outcomes: a cross sectional Japanese study. BMC Pregnancy and Childbirth. 2017;17(1).
15.
Soppert J, Lehrke M, Marx N, Jankowski J, Noels H. Lipoproteins and lipids in cardiovascular disease: from mechanistic insights to therapeutic targeting. Advanced Drug Delivery Reviews. 2020;159:4–33.
16.
Rinschen MM, Ivanisevic J, Giera M, Siuzdak G. Identification of bioactive metabolites using activity metabolomics. Nature Reviews Molecular Cell Biology. 2019;20(6):353–67.
17.
Karmaus PWF. Application of single cell methods in immunometabolism and immunotoxicology. Current Opinion in Toxicology. 2024;39:100488.
18.
Rana S, Lemoine E, Granger JP, Karumanchi SA. Preeclampsia. Circulation Research. 2019;124(7):1094–112.
19.
Sovio U, McBride N, Wood AM, Masconi KL, Cook E, Gaccioli F, et al. 4-Hydroxyglutamate is a novel predictor of pre-eclampsia. International Journal of Epidemiology. 2020;49(1):301–11.
20.
Diekan AG, Mohsin LA, Aljebori HD. Evaluation of patients with preeclampsia Some Biochemical Parameters and Hormones in Iraqi women. IJMSCRR. 2023;6(2):515–8.
21.
Al-Adami MS, Wajdi W, Abbas RA. Human chorionic gonadotropin and testosterone in Normal and Preeclamptic Pregnancies in Relation to Fetal sex. Al-Kindy Col Med J. 2011;7(2):1–8.
22.
Hu M, Li J, Baker PN, Tong C. Revisiting preeclampsia: a metabolic disorder of the placenta. The FEBS Journal. 2022;289(2):336–54.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
